Oberland Capital

Biohaven Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative treatments for neurological diseases and other therapeutic areas. The company focuses on life-changing therapies targeting conditions such as neuromuscular disorders, metabolic diseases, obsessive-compulsive disorder, and various forms of cancer. Its diverse pipeline includes late-stage product candidates that utilize mechanisms such as calcitonin gene-related peptide receptor antagonists, glutamate modulators, and myeloperoxidase inhibitors. Notable candidates in its pipeline include BHV3000-301, BHV3000-302, and BHV3000-303, among others. Biohaven's commitment to addressing unmet medical needs positions it as a significant player in the biopharmaceutical landscape.

Verastem, Inc. is a biopharmaceutical company dedicated to developing and commercializing innovative treatments aimed at improving the survival and quality of life for cancer patients. Based in Needham, Massachusetts, Verastem markets COPIKTRA (duvelisib), an oral medication indicated for adult patients with relapsed or refractory chronic lymphocytic leukemia and follicular lymphoma after multiple prior therapies. In addition to this approved therapy, the company is advancing its pipeline with the focal adhesion kinase inhibitor defactinib, which is being studied in combination with immunotherapies for various cancers, including pancreatic and ovarian cancers, as well as non-small cell lung cancer. Verastem's research emphasizes inhibiting critical signaling pathways that promote cancer cell survival and tumor growth, particularly those associated with the RAS/MAPK pathway. The company has formed collaborative agreements with Yakult Honsha Co., Ltd. and CSPC Pharmaceutical Group Limited to enhance its development efforts. Founded in 2010, Verastem continues to focus on late-stage development of its anticancer agents.

Verastem, Inc. is a biopharmaceutical company dedicated to developing and commercializing innovative treatments aimed at improving the survival and quality of life for cancer patients. Based in Needham, Massachusetts, Verastem markets COPIKTRA (duvelisib), an oral medication indicated for adult patients with relapsed or refractory chronic lymphocytic leukemia and follicular lymphoma after multiple prior therapies. In addition to this approved therapy, the company is advancing its pipeline with the focal adhesion kinase inhibitor defactinib, which is being studied in combination with immunotherapies for various cancers, including pancreatic and ovarian cancers, as well as non-small cell lung cancer. Verastem's research emphasizes inhibiting critical signaling pathways that promote cancer cell survival and tumor growth, particularly those associated with the RAS/MAPK pathway. The company has formed collaborative agreements with Yakult Honsha Co., Ltd. and CSPC Pharmaceutical Group Limited to enhance its development efforts. Founded in 2010, Verastem continues to focus on late-stage development of its anticancer agents.

ImmunityBio, Inc. is an immunotherapy company focused on developing innovative treatments that enhance the body's immune response to combat various cancers without relying on high-dose chemotherapy. The company's product pipeline includes a memory T-cell cancer vaccine, albumin-linked chemotherapeutics, a novel IL-15 cytokine superagonist known as Anktiva, checkpoint inhibitors, and various vaccine therapies targeting specific tumor-associated antigens. Incorporated in 2014 and headquartered in El Segundo, California, ImmunityBio aims to address multiple tumor types, including bladder, lung, and colorectal cancers, as well as glioblastoma. The company is a subsidiary of NantWorks, LLC, and is actively engaged in clinical development to bring its next-generation immuno- and cellular therapies to market.

ImmunityBio, Inc. is an immunotherapy company focused on developing innovative treatments that enhance the body's immune response to combat various cancers without relying on high-dose chemotherapy. The company's product pipeline includes a memory T-cell cancer vaccine, albumin-linked chemotherapeutics, a novel IL-15 cytokine superagonist known as Anktiva, checkpoint inhibitors, and various vaccine therapies targeting specific tumor-associated antigens. Incorporated in 2014 and headquartered in El Segundo, California, ImmunityBio aims to address multiple tumor types, including bladder, lung, and colorectal cancers, as well as glioblastoma. The company is a subsidiary of NantWorks, LLC, and is actively engaged in clinical development to bring its next-generation immuno- and cellular therapies to market.

Zealand Pharma A/S is a biotechnology company based in Copenhagen, Denmark, specializing in the discovery and development of peptide-based medicines. The company has a growing proprietary pipeline that includes several clinical candidates such as glepaglutide for short bowel syndrome and dasiglucagon for diabetes management and congenital hyperinsulinism. Zealand's first developed medicine, lixisenatide, is a once-daily GLP-1 analogue for Type 2 diabetes, marketed globally outside the US. The company has established collaborations with major pharmaceutical partners, including Sanofi, Helsinn Healthcare, and Boehringer Ingelheim, enhancing its product offerings and expanding its reach in the market. Zealand Pharma is committed to advancing innovative therapies, with multiple projects in various stages of clinical development and preclinical research.

Centessa Pharmaceuticals is a clinical-stage biopharmaceutical company focused on innovating the drug development process through an asset-centric research and development model. The company manages a diverse portfolio of therapeutics across several therapeutic areas, including SerpinPC for Hemophilia A and B, LB101 for solid tumors, ORX750 for Narcolepsy Type 1 and other sleep disorders, and MGX292 for pulmonary arterial hypertension. Each therapeutic program is developed by a dedicated subsidiary, leveraging a centralized infrastructure and experienced management team to ensure efficient advancement of its pipeline assets.

Esperion discovers and develops pharmaceutical products for the treatment of cardiovascular and metabolic diseases. Esperion intends to commercialize a novel class of drugs that focuses on a new treatment approach called "HDL Therapy," which is based on the Company's understanding of high-density lipoprotein, or HDL, function.

Mirum Pharmaceuticals is a biopharmaceutical company dedicated to developing and commercializing innovative therapies for debilitating liver diseases. Founded in 2018 and headquartered in Foster City, California, Mirum's lead product candidate is maralixibat, an investigational oral drug currently in Phase 3 clinical trials targeting progressive familial intrahepatic cholestasis, Alagille syndrome, and biliary atresia. The company’s approved product, Livmarli, is aimed at alleviating cholestatic pruritus in patients with Alagille syndrome. In addition to maralixibat, Mirum is also advancing the development of volixibat, which is intended for treating intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. Through its focused pipeline, Mirum aims to address significant unmet medical needs in rare and orphan liver diseases.

Primmune Therapeutics, Inc. is a biotechnology company based in San Diego, California, founded in 2017. The company specializes in developing small molecule, orally administered toll-like receptor 7 (TLR7) agonists aimed at enhancing innate immunity for cancer immunotherapy. Its TLR7 agonists are designed to stimulate the immune system by producing cytokines and chemokines that boost cellular responses and activate natural killer cells. This approach is intended to complement existing cancer treatments, such as checkpoint inhibitors, improving overall response rates and treatment durability. Primmune Therapeutics' innovative therapies target both acute and chronic viral infections, as well as metastatic diseases, while also promoting B-cell proliferation and activation.

NorthStar Medical Radioisotopes, LLC, founded in 2006 and based in Madison, Wisconsin, specializes in developing technologies and raw materials for the nuclear medicine market in the United States. As a subsidiary of NorthStar Medical Technologies, the company addresses critical supply challenges in the production of medical isotopes, particularly Molybdenum-99 and Technetium-99m, which are essential for diagnostic imaging in various medical fields, including neurology, oncology, and cardiology. NorthStar also produces therapeutic isotopes such as Actinium-225 and Bismuth-213 for treating incurable diseases like cancer and HIV. The company’s innovative RadioGenix System enables the production of Tc-99m from non-uranium based molybdenum-99, providing a reliable and efficient alternative to traditional methods. NorthStar Medical Radioisotopes is committed to enhancing patient care and advancing clinical research through its patented technologies and high-quality radioisotope products.

Impact Biomedicines, Inc. is a biopharmaceutical company focused on the research, development, and commercialization of innovative treatments for patients with myeloproliferative neoplasms and other cancers. Founded in 2016 and headquartered in San Diego, California, the company is primarily centered on its lead product, fedratinib, a potent and selective oral small molecule JAK2 kinase inhibitor. Fedratinib is being developed for the treatment of myelofibrosis and polycythemia vera, with additional potential applications in acute myeloid leukemia and colorectal cancer. As of February 2018, Impact Biomedicines operates as a subsidiary of Bristol-Myers Squibb Company.

Melinta Therapeutics, Inc. is a commercial-stage pharmaceutical company based in Morristown, New Jersey, specializing in the discovery, development, and commercialization of anti-infective therapies for bacterial infections in North America. The company offers a range of antibiotics, including Baxdela, Vabomere, Orbactiv, and Minocin, targeting various serious bacterial infections such as acute bacterial skin and skin structure infections (ABSSSIs) and gram-negative infections. Melinta is actively advancing its investigational antibiotic, delafloxacin, which is currently in Phase 3 development for ABSSSIs. Additionally, the company is engaged in research to develop new classes of antibiotics aimed at combating drug-resistant pathogens, particularly the ESKAPE group responsible for many hospital-acquired infections. Through its innovative approaches, Melinta Therapeutics addresses the urgent need for new therapies against drug-resistant infections, a critical public health challenge today.

ClearPoint Neuro, Inc., established in 1998 and headquartered in Irvine, California, operates as a medical device company specializing in minimally invasive neurosurgical procedures guided by direct magnetic resonance imaging (MRI). The company's primary product is the ClearPoint system, designed for precise insertion of catheters, electrodes, and laser fibers to treat neurological conditions such as deep-brain stimulation and biopsy. Additionally, ClearPoint Neuro has product candidates like the ClearTrace system for cardiac applications, aiming to expand its offerings in MRI-guided procedures. The company collaborates with renowned institutions like Johns Hopkins University and Mayo Clinic to develop innovative therapies and has a strategic focus on improving patient outcomes through precise neurological interventions.

ClearPoint Neuro, Inc., established in 1998 and headquartered in Irvine, California, operates as a medical device company specializing in minimally invasive neurosurgical procedures guided by direct magnetic resonance imaging (MRI). The company's primary product is the ClearPoint system, designed for precise insertion of catheters, electrodes, and laser fibers to treat neurological conditions such as deep-brain stimulation and biopsy. Additionally, ClearPoint Neuro has product candidates like the ClearTrace system for cardiac applications, aiming to expand its offerings in MRI-guided procedures. The company collaborates with renowned institutions like Johns Hopkins University and Mayo Clinic to develop innovative therapies and has a strategic focus on improving patient outcomes through precise neurological interventions.